Novartis (NVS) Chief Executive Vas Narasimhan and Paul Hudson, his counterpart at Sanofi (SNY) said Wednesday that EU "price controls and austerity measures" are decreasing the bloc's attractiveness for pharmaceutical companies.
In a letter to the Financial Times, Narasimhan and Hudson said that the US and China are trying to boost innovation, while in Europe "launch prices are suppressed, patented medicines' growth capped, and prices reduced when new applications are found."
"We see a strong outlook for the US -- thanks to policies and regulations conducive to fast and broad patient access to innovative medicines. Unfortunately, this cannot be said for Europe," the CEOs said.
"Against a backdrop of waning European biopharma competitiveness, the uncertainty of tariffs is further reducing incentives to invest in the EU," the letter said.
"Europe has leading universities, talent and hospitals. With deregulation and an attractive market for innovation, it can succeed. However, it must act decisively and urgently or decline will set in and departure of companies will accelerate," the letter said.
The European Commission didn't immediately respond to a request for comment by MT Newswires.
Price: 110.14, Change: -1.27, Percent Change: -1.14
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。